Research Progress on the Role and Mechanism of ABO Genes Promoter Methylation in the Weakened Expression of ABO Blood Group Antigens in Tumors

doi:10.3969/j.issn.1671-2587.2025.02.020

JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE ›› 2025, Vol. 27 ›› Issue (2): 283-288.DOI: 10.3969/j.issn.1671-2587.2025.02.020

Research Progress on the Role and Mechanism of ABO Genes Promoter Methylation in the Weakened Expression of ABO Blood Group Antigens in Tumors

LI Yao, SHI Minghao, SHEN Zhongjun, WANG Xin, ZHAO Liyan

Department of Blood Transfusion, the Second Hospital of Jilin University, Jilin Changchun 130041

Received:2024-12-01 Online:2025-04-20 Published:2025-04-17

Abstract

Abstract: ABO blood group antigens are expressed on the membranes of many tumor cells, but in some cancer patients, a weakened expression of A and B blood group antigens on tumor cells can be observed, which is often associated with tumor progression. The role and mechanism of the weakened expression of ABO blood group antigens in the occurrence and development of tumors are still unclear. Recent studies have shown that the methylation status of CpG islands in the promoter region of ABO genes may be related to the expression of ABO blood group antigens. This article aims to provide a brief review of the role and mechanism of ABO genes promoter methylation in the weakened expression of ABO blood group antigens in tumors.

Key words: ABO blood group antigens, CpG islands, Methylation, Cancer

CLC Number:

R730.2R446.6

LI Yao, SHI Minghao, SHEN Zhongjun, WANG Xin, ZHAO Liyan. Research Progress on the Role and Mechanism of ABO Genes Promoter Methylation in the Weakened Expression of ABO Blood Group Antigens in Tumors[J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2025, 27(2): 283-288.

References

[1] AYMARD J P.Karl Landsteiner(1868-1943)and the discovery of blood groups[J].Transfus Clin Biol,2012, 19(4/5):244-248.
[2] LEÓN-ATANCE P,MORENO-MATA N,GONZÁLEZ-ARAGONESES F,et al.Prognostic influence of loss of blood group A antigen expression in pathologic stage I non-small-cell lung cancer[J].Arch Bronconeumol,2012, 48(2):49-54.
[3] HAN J H,LEE H,KIM J K,et al.Clinical significance of decreased or loss of ABO blood group expression in acute myeloid leukaemia:a single-centre retrospective study[J].Vox Sang,2024,119(4):353-362.
[4] GAO S,BENNETT E P,REIBEL J,et al.Histo-blood group ABO antigen in oral potentially malignant lesions and squamous cell carcinoma—genotypic and phenotypic characterization[J].APMIS,2004,112(1):11-20.
[5] CHENNA D,MOHAN G,REDDY V R,et al.The disappearance of blood group antigens:a clue to the clinical diagnosis of leukemia[J].Transfus Apher Sci, 2019,58(1):48-49.
[6] VAN LOGHEM J J Jr,DORFMEIER H,VAN DER HART M.Two A antigens with abnormal serologic properties[J].Vox Sang,1957,2(1):16-24.
[7] SHAFIQ M,KARIM F.Red cell antigen loss in a patient with chronic myeloid leukemia:a case of ABO discrepancy[J]. Transfus Apher Sci,2015,52(1):103-104.
[8] CHIHARA Y,SUGANO K,KOBAYASHI A,et al.Loss of blood group A antigen expression in bladder cancer caused by allelic loss and/or methylation of the ABO gene[J].Lab Invest,2005,85(7):895-907.
[9] DABELSTEEN E,GAO S.ABO blood-group antigens in oral cancer[J].J Dent Res,2005,84(1):21-28.
[10] BHOOTRA S,JILL N,SHANMUGAM G,et al.DNA methylation and cancer:transcriptional regulation, prognostic,and therapeutic perspective[J].Med Oncol, 2023,40(2):71.
[11] SAGHAFINIA S,MINA M,RIGGI N,et al.Pan-cancer landscape of aberrant DNA methylation across human tumors[J].Cell Rep,2018,25(4):1066-1080.e8.
[12] KOMINATO Y,HATA Y,TAKIZAWA H,et al.Expression of human histo-blood group ABO genes is dependent upon DNA methylation of the promoter region[J].J Biol Chem, 1999,274(52):37240-37250.
[13] WORM J,KIRKIN A F,DZHANDZHUGAZYAN K N, et al.Methylation-dependent silencing of the reduced folate carrier gene in inherently methotrexate-resistant human breast cancer cells[J].J Biol Chem,2001,276(43):39990-40000.
[14] PROKHORTCHOUK E,HENDRICH B.Methyl-CpG binding proteins and cancer:are MeCpGs more important than MBDs?[J].Oncogene,2002,21(35):5394-5399.
[15] NAN X,NG H H,JOHNSON C A,et al.Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex[J].Nature,1998, 393(6683):386-389.
[16] CHIU R W K,CHIM S S C,WONG I H N,et al. Hypermethylation of RASSF1A in human and Rhesus placentas[J].Am J Pathol,2007,170(3):941-950.
[17] CHEN R,GAN Q Y,ZHAO S T,et al.DNA methylation of miR-138 regulates cell proliferation and EMT in cervical cancer by targeting EZH2[J].BMC Cancer,2022, 22(1):488.
[18] LE X,MU J H,PENG W Y,et al.DNA methylation downregulated ZDHHC1 suppresses tumor growth by altering cellular metabolism and inducing oxidative/ER stress-mediated apoptosis and pyroptosis[J].Theranostics, 2020,10(21):9495-9511.
[19] BIANCO-MIOTTO T,HUSSEY D J,DAY T K,et al.DNA methylation of the ABO promoter underlies loss of ABO allelic expression in a significant proportion of leukemic patients[J].PLoS One,2009,4(3):e4788.
[20] 邵明,吕先萍,汤平,等.急性白血病ABO抗原减弱患者与抗原正常患者的对比研究[J].中国实验血液学杂志,2017, 25(5):1307-1313.
[21] 宋倩倩,杨爽,郝芊萌,等.急性髓系白血病血型变化及其与治疗效果的关系[J].中国输血杂志,2024,37(6):700-704.
[22] 李军,刘宏旭,李玉,等.ABH及Lewis A组织-血型抗原表达与原发肺腺癌转移和预后的关系[J].中国现代医学杂志,2005,15(5):695-698.
[23] WANG C,ZHOU J J,WANG L L,et al.ABO blood groups and expression of blood group antigens of epithelial ovarian cancer in Chinese women[J].Cancer Med,2023, 12(6):7498-7507.
[24] ICHIKAWA D,HANDA K,WITHERS D A,et al.Histo-blood group A/B versus H status of human carcinoma cells as correlated with haptotactic cell motility:approach with A and B gene transfection[J].Cancer Res,1997,57(15): 3092-3096.
[25] HAHN M A,WU X W,LI A X,et al.Relationship between gene body DNA methylation and intragenic H3K9me3 and H3K36me3 chromatin marks[J].PLoS One,2011, 6(4):e18844.
[26] ANSTEE D J.The relationship between blood groups and disease[J].Blood,2010,115(23):4635-4643.
[27] FRANCHINI M,FAVALORO E J,TARGHER G,et al.ABO blood group,hypercoagulability,and cardiovascular and cancer risk[J].Crit Rev Clin Lab Sci,2012,49(4):137-149.
[28] FRANCHINI M,LIPPI G.The intriguing relationship between the ABO blood group,cardiovascular disease,and cancer[J].BMC Med,2015,13:7.
[29] DENTALI F,SIRONI A P,AGENO W,et al.ABO blood group and vascular disease:an update[J].Semin Thromb Hemost,2014,40(1):49-59.
[30] LUND R J,HUHTINEN K,SALMI J,et al.DNA methylation and transcriptome changes associated with cisplatin resistance in ovarian cancer[J].Sci Rep,2017,7(1):1469.
[31] 徐华,鲍国强,王宝燕,等.ABO基因启动子CpG岛甲基化与白血病的相关性[J].中国实验血液学杂志,2008,16(2): 240-246.
[32] 刘静. 部分白血病与骨髓增生异常综合征患者红细胞AH抗原表达与基因启动子CpG岛甲基化研究[D].苏州:苏州大学,2011.
[33] 邵明,汤平,吕先萍,等.ABO血型基因启动子甲基化水平在成人白血病和骨髓增生异常综合征中的临床意义和预后分析[J].中华内科杂志,2018,57(11):816-823.
[34] 邵明. DNA甲基化对白血病ABO基因表达的影响[D].郑州:郑州大学,2017.
[35] MIOLA M P,DE OLIVEIRA T C,GUIMARÃES A A G, et al.ABO discrepancy resolution in two patients with acute myeloid leukemia presenting the transient weak expression of A antigen[J].Hematol Transfus Cell Ther, 2024,46(1):85-88.
[36] YAMAMOTO F.Review:ABO blood group system—ABH oligosaccharide antigens,anti-A and anti-B,A and B glycosyltransferases,and ABO genes[J].Immunohematology,2004,20(1):3-22.
[37] LADD C,BOURKE M T,SCHERCZINGER C A,et al.A PCR-based strategy for ABO genotype determination[J].J Forensic Sci,1996,41(1):134-137.
[38] PRAKASH S,MOHAPATRA S,BHAGAVATHI M S,et al.Loss and reappearance of A antigen after chemotherapy leading to blood group discrepancy in acute myeloid leukemia:a case report[J].Lab Med,2021,52(5):509-513.
[39] SAKAMOTO Y,KAMADA M,IRAHARA M,et al.Differences in clinical significance of blood group antigens A,B,and H in carcinoma tissue in the uterine cervix[J].Gynecol Oncol,1986,25(2):195-203.
[40] GWIN J L,KLEIN-SZANTO A J,ZHANG S Y,et al.Loss of blood group antigen A in non-small cell lung cancer[J].Ann Surg Oncol,1994,1(5):423-427.
[41] 金沙,向东,刘曦,等. 疾病导致ABO血型抗原及抗体减弱的分析[J]. 临床输血与检验,2010,12(1):61-62.
[42] CHOI S J,KIM H K,SUH E J,et al.CEBPA double mutations associated with ABO antigen weakness in hematologic diseases[J].Blood Adv,2024,8(6):1487-1493.
[43] GAO S,WORM J,GULDBERG P,et al.Genetic and epigenetic alterations of the blood group ABO gene in oral squamous cell carcinoma[J].Int J Cancer,2004,109(2):230-237.
[44] NAMBIAR R K,NARAYANAN G,PRAKASH N P,et al.Blood group change in acute myeloid leukemia[J].Proc (Bayl Univ Med Cent),2017,30(1):74-75.
[45] TAMAI M,FUJISAWA S,NGUYEN T T T,et al.Creation of Philadelphia chromosome by CRISPR/Cas9-mediated double cleavages on BCR and ABL1 genes as a model for initial event in leukemogenesis[J].Cancer Gene Ther, 2023,30(1):38-50.
[46] YING Y L,TAO S D,HE Y M,et al.Molecular mechanism of an individual with weaken B phenotype in ABO blood group[J].Zhonghua Yi Xue Yi Chuan Xue Za Zhi, 2011,28(4):397-400.
[47] 刘静,李志强.部分恶性血液病患者红细胞A、H抗原表达与基因启动子CpG岛甲基化研究[J].临床输血与检验, 2011,13(3):205-211.
[48] 庞辉. 急性白血病致ABO血型变异1例[J]. 临床输血与检验,2012,14(2):183-184.
[49] TAKAHASHI Y,KUBO R,SANO R,et al.Histone deacetylase inhibitors suppress ABO transcription in vitro,leading to reduced expression of the antigens[J].Transfusion,2017,57(3):554-562.
[50] KRONSTEIN-WIEDEMANN R,KÜNZEL S R, THIEL J,et al.Role of MiRNA in the regulation of blood group expression[J].Transfus Med Hemother,2024, 51(4):237-251.
[51] DABELSTEEN E.ABO blood group antigens in oral mucosa.What is new?[J].J Oral Pathol Med,2002,31(2): 65-70.
[52] VIDAL S,BRUYÈRE I,MALLERON A,et al.Non-isosteric C-glycosyl analogues of natural nucleotide diphosphate sugars as glycosyltransferase inhibitors[J].Bioorg Med Chem,2006,14(21):7293-7301.
[53] WANG K Y,HE Z X,JIN G,et al.Targeting DNA methyltransferases for cancer therapy[J].Bioorg Chem, 2024,151:107652.
[54] AUMER T,DÄTHER M,BERGMAYR L,et al.The type of DNA damage response after decitabine treatment depends on the level of DNMT activity[J].Life Sci Alliance,2024, 7(9):e202302437.
[55] NISHIYAMA A,NAKANISHI M.Navigating the DNA methylation landscape of cancer[J].Trends Genet,2021, 37(11):1012-1027.

Research Progress on the Role and Mechanism of ABO Genes Promoter Methylation in the Weakened Expression of ABO Blood Group Antigens in Tumors

RichHTML

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

About

Author

Journal

Access Statistics

Contact

[1]	LI Xiuli, CHE Shuping, CAO Rongyi. Platelet lncRNA in the Early Screening of Colon Cancer [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2025, 27(2): 200-206.
[2]	WANG Lingxia, LI Xiao, XU Shiliang, WANG Bo, YANG Huan. Knockdown of Hsa_Circ_0020080 Promotes Proliferation, Migration and Invasion of Human Breast Cancer Cells by Regulating Lipid Metabolism [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2025, 27(1): 34-47.
[3]	CHE Yang, LIU Zheng, ZHOU Xiaoyu. Retrospective Analysis of the Efficacy of Postoperative Plasma Transfusion in Patients with Primary Liver Cancer Undergoing Liver Resection [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2024, 26(6): 755-761.
[4]	CHEN Xin, SHAO Xiaobao, XUE Changwen, ZHOU Lin, ZHU Peiyuan. Experimental Study on Inhibition of the Interaction between Platelets and Tumor Cells by Tanshinone ⅡA [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2024, 26(2): 187-195.
[5]	XUE Changwen, SHAO Xiaobao, CHEN Xin, ZHOU Lin, ZHU Peiyuan. Experimental Study on Inhibition of Interaction between Platelets and Tumor Cells by Ginkgolide B [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2024, 26(2): 205-212.
[6]	ZHOU Renlong, LI Lingbo, YAN Yan, TANG Dandan. Comprehensive Analysis of Blood Group Gene CD36 in Pan Cancer [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2024, 26(2): 251-261.
[7]	ZHOU Renlong, HUANG Guoqing, LI Lingbo, TANG Dandan. Expression and Clinical Significance of Blood Group CD59 Gene in Pancreatic Cancer [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2024, 26(1): 101-109.
[8]	CHEN Shan, LIU Jingfu, LI Zhen, et al. Establishment of A Blood Transfusion Prediction Model for Perioperative Patients with Esophageal Cancer [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2023, 25(6): 743-748.
[9]	YOU Laiwei, CHENG Yong, GUO Jianrong. Research Progress on the Influence of ABO Blood Group on Venous Thromboembolism in Cancer Patients [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2023, 25(6): 857-861.
[10]	ZHENG Siqing, WANG Hao. The Research Progress of m6A Modification on the Drug Resistance of Tumors in Traditional Chemotherapy and New Targeted Therapies [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2023, 25(5): 706-720.
[11]	LUO Jingling, YANG Lei. Effect of Apheresis Platelets Transfusion on Proliferation and Metastasis of Hepatocellular Carcinoma Cells [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2023, 25(4): 456-460.
[12]	WANG Zhi-feng, SUN Hao, HU Dian, et al. LncRNAs ABHD11-AS1 Targets miR-133a to Upregulate EGFR Expression and Promote Ovarian Cancer cell Proliferation [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2022, 24(5): 574-581.
[13]	ZHOU Lin, CI Xuan, SHAO Xiao-bao, et al. Correlation between Perioperative Blood Transfusion and Postoperative Inflammatory Complications in Patients with Colorectal Cancer [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2022, 24(4): 416-421.
[14]	WU Jun-ying, WANG Ling-xia, WU Xi-xi, et al. NFKBIZ in Breast Cancer：Biological Function and Clinical Diagnostic Value [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2022, 24(4): 482-487.
[15]	LIU Yan-yan, ZHANG Ming-jun. Effect of Prognostic Nutritional Index on Postoperative Complications and Short-term Survival Rate for Patients with Advanced Gastric Cancer [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2022, 24(2): 230-234.